Guide · 9 min
The Hayfever Supplement Guide: What Actually Works (And What Needs More Proof)
From quercetin to probiotics — a clear-eyed look at nature's anti-allergy toolkit
In short
Quercetin consistently inhibits mast cell degranulation across multiple in vitro and preclinical models, suppressing release of histamine, β-hexosaminidase, PGD₂, leukotrienes, and pro-inflammatory cytokines. Multiple mechanistic pathways have been identified, with effective concentrations…
The supplement aisle problem
Walk into any health food shop in May and you'll find an entire shelf dedicated to hayfever: quercetin capsules, nettle tinctures, local honey jars labelled with hopeful claims, vitamin C powders, probiotic blends. The promises on the labels are often large. The evidence behind them is often small — but it isn't zero.
That distinction matters. Some of these supplements have genuinely interesting science behind them. Others are mechanistically plausible but clinically unproven. A few are more wishful thinking than medicine. Knowing the difference can help you make smarter choices about what's worth trying, what to treat with cautious optimism, and what to leave on the shelf.
This is not a list of miracle cures. It's an honest survey of where the evidence stands in 2025 — and what that evidence actually means for someone sneezing their way through pollen season.
The science
Quercetin: the most promising natural mast-cell stabiliser
If one supplement has earned serious scientific attention for hayfever, it's quercetin — a plant pigment found in onions, apples, capers, and kale.
The core mechanism is well-characterised. Mast cells in your nasal lining are the cells that release histamine when pollen arrives. Quercetin appears to act as a brake on that process through multiple pathways simultaneously. A 2024 study by Zhao, Ding, and Huang identified that quercetin acts as an agonist at inhibitory receptors on mast cells (the CD300f/CLM-1 family), triggering a signalling cascade that suppresses the calcium influx needed to release granules — and, with them, histamine. A separate 2025 study by the same group (DOI: 10.1002/ptr.8516) demonstrated this in a chronic urticaria model, showing reduced IgE-mediated mast cell activation via the same receptor family. A 2022 study by Alam et al. added another layer: quercetin also reduces the number of IgE receptors on mast cell surfaces, meaning fewer entry points for the allergic cascade to begin.
A 2025 systematic review and meta-analysis of preclinical studies (DOI: 10.3389/fphar.2025.1673712) corroborated these multi-target anti-allergic effects across numerous in vitro models, noting suppression of histamine, prostaglandin D₂, leukotrienes, and pro-inflammatory cytokines.
The critical caveat: effective concentrations in cell studies sit around 100 µM — a pharmacologically challenging level to achieve in human nasal tissue through oral supplementation alone. No RCTs have specifically tested quercetin for mast cell inhibition in allergic rhinitis patients. There's also a complexity: one study noted that prolonged high-dose exposure paradoxically increased some degranulation markers, suggesting that more isn't always better, and that dosing timing matters.
Confidence level: Moderate for the mechanism; low for clinical effect size in humans.
Probiotics: the most clinically supported option
Of everything in the supplement category, probiotics have the strongest human trial evidence for hayfever specifically.
Multiple systematic reviews and meta-analyses published between 2022 and 2025 — including Luo et al. (DOI: 10.3389/fimmu.2022.848279), Yan et al. (DOI: 10.15586/aei.v50i3.507), and Farahmandi et al. (DOI: 10.1177/19458924211073550) — consistently show modest but statistically significant reductions in nasal symptom scores, ocular symptoms, and quality-of-life measures during pollen season compared to placebo. Strain-specific benefits are clearest for Bifidobacterium longum BB536 and certain multi-strain formulas.
The mechanism runs through the gut-immune axis. Your gut microbiome shapes the balance between Th1 and Th2 immune responses — with the allergic response representing an over-activation of the Th2 side. Probiotics tip this balance back toward Th1 dominance, reducing IL-4, IL-5, and IgE while increasing regulatory signals such as IFN-γ and IL-10. These systemic effects reach the nasal mucosa, where reduced eosinophil infiltration translates to calmer tissue during pollen season.
The honest qualifier: intention-to-treat analyses in many individual trials yield non-significant results. Heterogeneity across studies is high, and most individual RCTs enrolled fewer than 100 participants. The effect sizes are real but modest — probiotics won't replace antihistamines during a peak exposure day, but they may soften your season's baseline.
Confidence level: Moderate.
Omega-3 fatty acids: stronger for prevention than treatment
EPA and DHA — the long-chain omega-3s in oily fish and fish oil — have a well-understood anti-inflammatory action. They compete with arachidonic acid for membrane incorporation, shifting eicosanoid production toward less inflammatory mediators including resolvins and 15-HEPE, while also suppressing Th2 cytokines and upregulating IL-10.
A 2019 meta-analysis by Zhang et al. (DOI: 10.1080/02770903.2019.1709866) found reductions in allergic disease outcomes in children when mothers supplemented during pregnancy, and a parallel systematic review by Vahdaninia et al. (DOI: 10.1016/j.anai.2018.12.008) confirmed reduced IgE sensitisation in offspring following perinatal omega-3 supplementation.
For adults with established allergic rhinitis, the picture is less clear. Preclinical data are robust, but large, high-quality RCTs targeting allergic rhinitis symptom scores specifically in adults are simply absent from the literature. Optimal EPA/DHA ratios and effective doses for this indication remain undefined.
Confidence level: Moderate for perinatal allergy prevention; low-to-moderate for adult symptom management.
Vitamin D: the association is real; the intervention evidence isn't
The pattern across studies is consistent: people with allergic rhinitis tend to have lower vitamin D levels than non-allergic controls, and deficiency correlates with more severe, persistent disease. The immunological rationale is solid — vitamin D receptors are expressed on virtually every immune cell, and deficiency skews immune responses toward Th2 dominance, suppresses regulatory T cells, and impairs the epithelial barrier integrity of nasal mucosa.
But — and this is an important but — a 2022 meta-analysis of 32 RCTs in children by Li et al. (DOI: 10.3390/nu14193947) found that supplementation did not reliably reduce allergic disease outcomes. The association between low vitamin D and worse allergy is well-established; the causality is not. It may be that allergic disease and its associated lifestyle changes (staying indoors, reduced sun exposure) cause lower vitamin D levels, rather than the reverse.
What this means practically: correcting a documented deficiency is a sensible health measure regardless. Treating vitamin D as a hayfever remedy in isolation is premature.
Confidence level: Moderate for the association; low for supplementation as a treatment.
Green tea (specifically 'Benifuuki'): promising, but strain-specific
EGCG — the main bioactive catechin in green tea — has robust preclinical evidence for mast cell stabilisation. It inhibits the kinases involved in IgE-triggered mast cell signalling, suppresses NF-κB activation, and reduces secretion of histamine, TNF-α, IL-6, and leukotrienes.
Two double-blind RCTs have tested this clinically, and both showed meaningful reductions in nasal and ocular symptom scores of 20–50% versus placebo. The critical detail: both used 'Benifuuki' cultivar green tea, which is specifically enriched with a methylated EGCG derivative (EGCG3″Me) not found in significant quantities in standard commercial green tea. No RCTs have demonstrated equivalent benefits from everyday green tea. So the clinical evidence is real but narrow — it supports a specific cultivar, not the general category.
Confidence level: Moderate for Benifuuki; low for standard green tea.
Vitamin C, nettle, bromelain, and magnesium: interesting mechanisms, thin human evidence
These four sit in a similar position: biologically plausible, some in vitro or early clinical data, but insufficient human trial evidence to make strong recommendations.
Vitamin C: Small studies from the 1990s found that 2 g/day reduced blood histamine by around 38%, and a 2013 study found IV ascorbic acid reduced serum histamine. The proposed mechanism — enhancing diamine oxidase activity, the enzyme that degrades histamine — is biologically coherent. But a 2025 RCT found no effect of 1,000 mg/day oral vitamin C on skin histamine responses in allergic rhinitis patients, and no large-scale trials exist.
Stinging nettle (Urtica dioica): A 2009 study by Roschek et al. (DOI: 10.1002/ptr.2763) demonstrated H1 receptor antagonism in vitro at IC50 values of 193–251 µg/mL. The extract also inhibited mast cell tryptase and COX-1/2. A small RCT (Bakhshaee et al., 2017; n=74) found some symptomatic benefit in allergic rhinitis. Whether the concentrations needed to block H1 receptors are achievable after oral dosing remains unknown.
Bromelain: The strongest evidence here is for acute sinusitis — a 2023 systematic review and meta-analysis (Leelakanok et al., DOI: 10.1177/02601060231173732) found modest but significant pain reduction across 9 studies, and RCTs in children show faster recovery times. Bromelain has also been shown to penetrate sinonasal mucosa (Passali et al., 2018). For allergic rhinitis specifically, only pilot data exist.
Magnesium: In vitro, magnesium chloride dose-dependently inhibits mast cell degranulation by blocking calcium influx. A 2025 study by Kazama et al. (DOI: 10.33594/000000793) showed mast cell degranulation dropped from ~94% to ~21% at high magnesium concentrations in rat peritoneal cells. Clinically, a single small 1990 RCT exists — underpowered, three decades old, and lacking validated outcome measures.
Dietary fibre and gut health: the bigger picture
High-fibre diets promote production of short-chain fatty acids (SCFAs) by gut bacteria, which support regulatory T-cell activity, strengthen epithelial barriers, and suppress IgE-mediated responses. Animal models show protective effects on allergic airway inflammation (Zhang et al., DOI: 10.1371/journal.pone.0147778), and the EAACI position paper (Venter et al., 2022, DOI: 10.1111/all.15430) supports fibre's role in immune health.
A complication: some fibres — particularly inulin — may paradoxically activate ILC2s and drive eosinophilia in certain contexts. This fibre-type specificity matters and isn't yet well understood in humans. No large RCTs specifically target allergic rhinitis with high-fibre dietary interventions.
Honey: a popular idea that doesn't hold up under scrutiny
The local honey theory is intuitive: if you eat small amounts of local pollen in honey, perhaps you'll gradually desensitise. The problem is the dose. A tablespoon of honey delivers an estimated 60–600 µg of total pollen protein daily, with allergen-specific fractions in the sub-microgram range. Sublingual immunotherapy delivers 10–20 µg of standardised major allergen daily — an order of magnitude more, in controlled doses, with verified allergen identity.
The single qualifying post-2011 RCT (Asha'ari et al., 2013, DOI: 10.5144/0256-4947.2013.469) used an impractical 1 g/kg/day dose alongside antihistamines and found no significant between-group difference in total symptom score. No meta-analysis pooling honey RCTs for allergic rhinitis exists, because there aren't enough comparable trials to pool. Any benefit from honey is more plausibly attributable to its polyphenol content than allergen desensitisation.
Confidence level: Low. No recommendation.
What this means for you
The supplements with the strongest evidence aren't replacing your antihistamine — they're working through different biological pathways that, together, may reduce your allergic baseline across the season.
Probiotics, taken consistently through spring, appear to modulate the immune environment that determines how your body responds to pollen in the first place. Quercetin, taken before exposures, may reduce how aggressively your mast cells fire. Adequate vitamin D supports the immune regulation your body needs to avoid overreacting. Oily fish twice a week nudges your inflammatory eicosanoid balance in a less reactive direction. Green tea can be a pleasant daily habit — just know that the studied benefits come from a specific cultivar.
None of this is dramatic. But hayfever management is cumulative. Anything that lowers your inflammatory baseline — even modestly — raises the pollen threshold at which symptoms break through.
The evidence landscape
Being honest about confidence levels matters here, because the supplement space is prone to overclaiming.
Where evidence is stronger (moderate confidence): Probiotics for seasonal AR symptom reduction; quercetin for mast cell stabilisation mechanisms; omega-3s for perinatal allergy prevention; vitamin D deficiency as a risk modifier.
Where evidence is promising but preliminary (low confidence): Vitamin C and histamine degradation; nettle for H1 blockade; bromelain for sinus symptoms; fibre for gut-immune axis modulation; EGCG from Benifuuki green tea.
Where evidence is weak and inconsistent: Magnesium for mast cell stabilisation in humans; inulin/PHGG for immune tolerance in hayfever; honey for symptom relief.
A consistent pattern across nearly all these areas: in vitro and animal model data are rich; human RCTs in allergic rhinitis populations with validated outcome measures (Total Nasal Symptom Score, RQLQ) are thin. Mechanistic plausibility should not be confused with clinical proof.
What Haelo recommends
Based on the current evidence, here's where each supplement sits in a practical hayfever toolkit:
Start 4–6 weeks before your season begins:
- Probiotics — look for formulas featuring Bifidobacterium longum BB536 or multi-strain combinations with documented allergic rhinitis trial data. Take daily, consistently. The immune-modulating effects build over weeks, not days.
Take daily through your season:
- Quercetin — standard doses in supplements range from 500–1,000 mg/day, often formulated with bromelain or lecithin to improve absorption. Take in the morning or before anticipated outdoor exposure. Avoid very high doses for extended periods until duration-dependent effects are better characterised.
- Omega-3s (EPA/DHA) — 1–2 g/day of combined EPA/DHA from fish oil or algae-based sources. Prioritise getting to 2 portions of oily fish weekly if you prefer food sources.
Check your baseline, then maintain:
- Vitamin D — get your levels checked before supplementing. If deficient (common in the UK population), repletion to adequate levels (75–100 nmol/L) supports the immune regulation that makes allergy management easier. Standard supplementation of 1,000–2,000 IU/day is appropriate for most adults over winter and spring.
Worth including as part of a broader diet, not as a standalone intervention:
- Fibre-rich foods — vegetables, legumes, oats, and varied whole grains. Prioritise diversity over quantity of any single fibre type.
- Polyphenol-rich foods — berries, dark chocolate (>70% cocoa), green and black tea. The preclinical evidence for quercetin-independent anti-allergic effects is robust enough to make these sensible dietary choices even without clinical trial confirmation.
- Benifuuki green tea — if you can source it (it's available from specialist Japanese tea retailers), the evidence for this specific cultivar is meaningfully stronger than for standard green tea.
What to skip:
- Honey for hayfever desensitisation — the dose of allergen is far too low and too variable to achieve immunological tolerance. Enjoy it for other reasons.
- High-dose single supplements without evidence — more isn't more when mechanism and dose-response aren't established.
As always, if you're on medication — particularly anticoagulants, immunosuppressants, or antihistamines — check with your GP or pharmacist before adding new supplements to your routine. Quercetin and bromelain both have mild anticoagulant activity at high doses.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
Does quercetin inhibit mast cell degranulation?
Quercetin consistently inhibits mast cell degranulation across multiple in vitro and preclinical models, suppressing release of histamine, β-hexosaminidase, PGD₂, leukotrienes, and pro-inflammatory cytokines. Multiple mechanistic pathways have been identified, with effective concentrations demonstrated at 100 µM in human mast cell lines, showing comparable but slightly inferior performance to cromolyn in direct comparisons. A 2025 systematic review and meta-analysis of preclinical studies corroborates these multi-target anti-allergic effects, though direct clinical evidence in allergic rhinitis patients is lacking.
How it works
Quercetin acts as an agonist at inhibitory CD300 family receptors (CLM-1/CD300f) on mast cells, triggering SHP-1 phosphorylation that suppresses downstream MyD88/IKK/NF-κB signaling and PI3K/AKT/Rac1/Cdc42 pathways, thereby reducing calcium influx, F-actin cytoskeletal remodeling, and granule exocytosis; additional mechanisms include downregulation of FcεRI surface expression and heme oxygenase-1 induction.
Confidence: moderate
Do omega-3 fatty acids reduce allergic inflammation?
Omega-3 fatty acids demonstrate anti-inflammatory effects relevant to allergic disease, with multiple systematic reviews and meta-analyses suggesting modest benefits, particularly when supplemented perinatally or during early childhood. Evidence from RCTs shows reductions in IgE-mediated sensitization and some allergic outcomes in offspring, though effects on established allergic rhinitis in adults remain less well characterized. Preclinical mechanistic data are robust, but human clinical trial evidence specific to allergic rhinitis symptom reduction is limited and inconsistent.
How it works
Omega-3 fatty acids (EPA and DHA) compete with arachidonic acid for membrane incorporation and enzymatic processing, shifting eicosanoid production toward less pro-inflammatory mediators such as resolvins and 15-HEPE, while also suppressing Th2 cytokines (IL-4, IL-13) and upregulating anti-inflammatory IL-10. These actions collectively reduce mast cell degranulation, eosinophil activity, and downstream allergic inflammatory cascades.
Confidence: moderate
Does vitamin C lower histamine levels?
Small human studies and observational data suggest an inverse relationship between plasma vitamin C levels and blood histamine concentrations, with supplementation (1–2 g/day orally or 7.5 g IV) associated with measurable histamine reductions. A 2013 study found intravenous ascorbic acid significantly decreased serum histamine in allergic and non-allergic patients, and a 1992 RCT reported ~38% reduction in blood histamine with 2 g/day over two weeks. However, a 2025 RCT found no significant effect of oral vitamin C (1000 mg/day for 7 days) on skin wheal responses to histamine or dust mite allergen in allergic rhinitis patients, highlighting inconsistency across study designs.
How it works
Ascorbic acid is proposed to enhance diamine oxidase (DAO) activity—the primary enzyme responsible for extracellular histamine degradation—and may stabilize mast cells by modulating intracellular cAMP levels, raising the threshold for degranulation. In vitro evidence also suggests ascorbate can chemically degrade histamine via hydrogen peroxide generation in the presence of Cu²⁺ ions, though the physiological relevance of this pathway in humans remains unestablished.
Confidence: low
Does vitamin D deficiency worsen allergies?
Observational and mechanistic evidence consistently links vitamin D deficiency to worsened allergic disease severity, including allergic rhinitis, atopic dermatitis, and asthma, with studies reporting that the majority of allergic rhinitis patients have insufficient vitamin D levels and that deficiency correlates with more severe, persistent disease classifications. However, intervention trials—including a 2022 meta-analysis of 32 RCTs in children—have not demonstrated that supplementation reliably reduces allergic disease outcomes, suggesting the relationship is associative rather than clearly causal. Results across studies remain inconsistent, with variability attributed to age, geography, genetic factors, and confounders such as sun exposure and dietary habits.
How it works
Vitamin D modulates both innate and adaptive immunity via vitamin D receptors expressed on most immune cells; deficiency skews the Th1/Th2 balance toward Th2 dominance, suppresses regulatory T cell (Foxp3+ Treg) induction, and impairs IL-10 production—collectively promoting the IgE-mediated, eosinophilic inflammation that underlies allergic rhinitis. Additionally, vitamin D supports epithelial barrier integrity, gut microbiome homeostasis, and DAO enzyme activity relevant to histamine regulation, providing multiple plausible pathways through which deficiency could amplify allergic responses.
Confidence: moderate
Do high-fibre diets reduce allergic disease?
High-fibre diets show promising but inconsistent evidence for reducing allergic disease, with the strongest signals seen for atopic dermatitis and house dust mite sensitisation in observational human studies and mechanistically rich animal models. Evidence for allergic rhinitis and asthma is more mixed: general dietary fibre and SCFA production appear protective in preclinical models, but specific fibres such as inulin have been shown to exacerbate type 2 airway inflammation via ILC2 activation and eosinophilia. No large-scale RCTs specifically targeting allergic rhinitis outcomes with high-fibre dietary interventions have been identified.
How it works
Fermentable dietary fibres are metabolised by gut microbiota into short-chain fatty acids (SCFAs—acetate, propionate, butyrate), which modulate immune responses via the gut-lung and gut-skin axes by suppressing IgE-mediated mast cell activation, promoting regulatory T cell activity, strengthening epithelial barrier integrity, and shaping the lung's immunological environment. However, certain fibres (e.g., inulin) can paradoxically drive Bacteroidetes-mediated bile acid production and ILC2 activation, promoting pro-allergic type 2 inflammation in a context-dependent manner.
Confidence: low
Can PHGG or inulin improve immune tolerance?
Inulin-type fructans (including GOS/inulin combinations) show preclinical evidence for promoting immune tolerance biomarkers in mouse allergy models, including upregulation of IgG2a, IgA, TGF-β, IL-10, and IFN-γ alongside reduced allergic markers, with one systematic review and meta-analysis supporting prebiotic supplementation for allergy prevention in infants. PHGG demonstrates moderate evidence for general immune modulation via SCFA production and Treg induction in healthy human cohorts, but neither PHGG nor inulin has been tested in allergic rhinitis-specific human trials. The overall clinical evidence for immune tolerance improvement in IgE-mediated allergic conditions such as hayfever remains insufficient.
How it works
Both PHGG and inulin act as prebiotics fermented by gut microbiota (Bifidobacterium, Lactobacillus) to produce short-chain fatty acids such as butyrate and propionate, which promote regulatory T-cell differentiation, strengthen gut barrier integrity, and shift immune responses away from pro-inflammatory and Th2-skewed profiles toward tolerance-associated cytokines (TGF-β, IL-10). GOS/inulin combinations additionally modulate MyD88 signaling and propionate levels, providing a plausible mechanistic link to reduced allergic sensitization.
Confidence: low
Does bromelain improve sinus symptoms?
Bromelain shows moderate evidence for improving sinus symptoms, particularly in acute sinusitis, with RCTs demonstrating faster recovery times (6.66 vs 7.95 days) and higher rates of complete nasal inflammation resolution (85% vs 40% placebo) especially in pediatric populations. A 2023 systematic review and meta-analysis confirmed modest but statistically significant pain reduction (MD -0.27; 95% CI: -0.45 to -0.08 across 9 studies), and a 2018 study demonstrated meaningful tissue penetration into sinonasal mucosa in CRS patients. Evidence for chronic rhinosinusitis and allergic rhinitis specifically remains weak, with only small pilot studies and mechanistic data available.
How it works
Bromelain, a proteolytic enzyme mixture derived from pineapple stems, reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), modulates immune cell activity (macrophages, T cells, NK cells), and exerts mucolytic and anti-edema effects that facilitate mucus drainage and reduce sinonasal inflammation. Its demonstrated penetration into sinonasal mucosa supports a plausible local anti-inflammatory action at the site of pathology.
Confidence: moderate
Does nettle extract block histamine receptors?
Nettle (Urtica dioica) extract demonstrates H1 receptor antagonist and negative agonist activity in vitro, with IC50 values of 251 μg/mL and 193 μg/mL respectively, as quantified by Roschek et al. (2009). Beyond H1 receptor blockade, the extract also inhibits mast cell tryptase, COX-1, COX-2, and prostaglandin D2 synthase, suggesting a multi-target anti-allergic profile. A small RCT (Bakhshaee et al., 2017, n=74) provides limited clinical support for symptomatic benefit in allergic rhinitis, though direct mechanistic confirmation in humans is lacking.
How it works
Nettle extract bioactives competitively block histamine binding to H1 receptors while also acting as negative agonists that suppress baseline receptor activity independent of ligand presence, providing dual-layer inhibition of histamine-mediated signaling. Flavonoid constituents such as quercetin and phenolic acids (e.g., 5-O-caffeoylquinic acid) likely contribute to mast cell membrane stabilization, further reducing histamine release upstream.
Confidence: low
Do probiotics reduce hayfever severity?
Multiple systematic reviews and meta-analyses (2016–2025) indicate that probiotics produce modest but statistically significant reductions in allergic rhinitis symptom scores and quality of life measures compared to placebo, particularly during peak pollen season. Strain-specific effects have been observed, with Bifidobacterium longum BB536 and multi-strain formulas showing the most consistent benefits for nasal symptoms (sneezing, rhinorrhea, congestion) and ocular symptoms, alongside reductions in IgE and eosinophil levels. However, intention-to-treat analyses frequently yield non-significant results, and overall conclusions are tempered by substantial heterogeneity across trials.
How it works
Probiotics modulate the gut-immune axis by shifting the Th1/Th2 cytokine balance away from the allergic Th2-dominant response, reducing pro-inflammatory mediators (IL-4, IL-5, IgE, eosinophils) while upregulating regulatory signals (IFN-γ, IL-10, TGF-β), which in turn dampens downstream nasal mucosal inflammation and eosinophil infiltration. This systemic immunomodulation originates through interactions between probiotic bacteria and gut epithelial and immune cells, with effects propagating to distant mucosal sites including the nasal epithelium.
Confidence: moderate
Do polyphenol-rich foods (berries, dark chocolate, green tea) reduce allergic inflammation in hayfever sufferers independently of quercetin content?
Preclinical evidence consistently supports quercetin-independent anti-allergic effects of polyphenols from berries (anthocyanins, procyanidins), dark chocolate (epicatechins, procyanidins), and green tea (EGCG, catechins), demonstrating mast cell stabilization, reduced histamine and β-hexosaminidase release (>70% in some assays), and suppressed IgE-mediated signaling cascades. In animal models of allergic airway inflammation, these compounds reduced serum IgE, restored Th1/Th2 balance, and lowered mucus production by 40–60%. However, no published RCTs have specifically tested these non-quercetin polyphenols in hayfever patients using validated clinical endpoints such as Total Nasal Symptom Score (TNSS) or nasal cytokine profiling.
How it works
Non-quercetin polyphenols inhibit allergic inflammation through multiple complementary pathways: EGCG and catechins block FcεRI-mediated mast cell signaling kinases (Syk, Lyn, PLCγ, PKC) and suppress NF-κB/MAPK activation; epicatechins and procyanidins inhibit IgE-allergen cross-linking and downregulate FcεRI expression on mast cells; resveratrol suppresses TSLP synthesis in mast cells and shifts Th1/Th2 immune balance — all independently of quercetin-specific mechanisms.
Confidence: low
Does regular green tea consumption reduce allergic rhinitis symptom severity through EGCG-mediated anti-inflammatory pathways?
EGCG and its O-methylated derivative (EGCG3″Me), particularly from 'Benifuuki' green tea, demonstrate clinically meaningful reductions in allergic rhinitis symptom severity in double-blind RCTs, with nasal and ocular symptom scores declining 20-50% versus placebo over 7-13 weeks of daily consumption. However, this evidence is specific to 'Benifuuki' cultivar tea enriched with EGCG3″Me; no RCTs demonstrate equivalent effects from standard commercial green tea containing conventional EGCG alone. Preclinical models consistently support EGCG-mediated anti-inflammatory activity in allergic airway inflammation, but the translational gap between these findings and standard green tea consumption in humans remains unresolved.
How it works
EGCG and EGCG3″Me suppress allergic inflammation primarily by stabilizing mast cells and inhibiting degranulation, reducing secretion of pro-inflammatory mediators including TNF-α, IL-6, IL-8, MIP-1α, leukotrienes, and histamine via attenuation of ERK and NF-κB signaling pathways and mitochondrial calcium dysregulation. Additional mechanisms include modulation of the Treg/Th17 and Th1/Th2 balance, scavenging of reactive oxygen species, and inhibition of NLRP3 inflammasome activation, collectively dampening the type-I hypersensitivity cascade underlying allergic rhinitis.
Confidence: moderate
Does magnesium supplementation reduce allergic rhinitis severity through its role in mast cell stabilisation?
There is preliminary mechanistic evidence that magnesium stabilises mast cells and inhibits histamine release, with in vitro data showing dose-dependent reductions in rat peritoneal mast cell degranulation (from ~94% to ~21% at 100 mM MgCl₂). However, clinical evidence in allergic rhinitis remains very limited, consisting of a small 1990 double-blind RCT using oral magnesium pidolate (38 subjects) and preliminary intranasal magnesium sulfate data, neither providing robust quantitative symptom outcomes such as TNSS. No large-scale human trials confirm that magnesium supplementation meaningfully reduces allergic rhinitis severity via mast cell stabilisation.
How it works
Magnesium acts as an endogenous calcium channel blocker, competitively inhibiting calcium influx through channels including TRPM7, thereby suppressing the calcium-dependent degranulation cascade in mast cells and reducing release of histamine and proinflammatory mediators such as IL-4 and IL-13. It also appears to potentiate the inhibitory effects of adrenaline on mast cell degranulation, suggesting a complementary modulatory role in allergic responses.
Confidence: low
What is the state of post-2011 randomised trials of pollen-spiked or local honey on allergic rhinitis symptoms — design, dose, outcome measures, and effect sizes?
Only one post-2011 RCT has tested honey ingestion for allergic rhinitis (Asha'ari et al., 2013): a placebo-controlled trial of high-dose unspecified honey (1 g/kg/day) as adjunct to loratadine in 40 adults, which found significant within-group improvement in individual symptoms (nasal obstruction, itching, sneezing) in the honey group sustained to week 8, but no statistically significant between-group difference in total symptom score (TSS 11.9 vs 13.1, p=0.428). No post-2011 RCT has specifically tested pollen-spiked or local honey for allergic rhinitis; the only such pre-2011 RCT (Rajan et al., 2002) found no benefit of local honey over corn syrup control.
How it works
The proposed mechanism for local or pollen-spiked honey involves oral tolerance induction via repeated low-dose allergen exposure analogous to sublingual immunotherapy, potentially modulating IgE-mediated responses; honey's non-specific anti-inflammatory and antioxidant properties (independent of pollen content) may additionally attenuate nasal mucosal inflammation.
Confidence: low
Has any meta-analysis of dietary honey interventions for allergic rhinitis been published since 2011, and what does it conclude?
No dedicated meta-analysis pooling multiple RCTs of dietary honey for allergic rhinitis has been published since 2011, primarily because too few comparable controlled trials exist. The most relevant systematic review (Newman, 2014) identified only one small positive RCT (Asha'ari et al., 2013; n=40, high-dose Tualang honey 1g/kg/day as adjunct to loratadine) and one older negative trial using commercial honey, concluding only a weak recommendation for local honey as an adjunct therapy. Subsequent narrative and mini-reviews (2021–2023) consistently characterize the evidence as promising but preliminary, with no pooled quantitative effect size estimable from the available data.
How it works
Honey's proposed benefit in allergic rhinitis is attributed to anti-inflammatory and immunomodulatory properties—including polyphenol-mediated suppression of Th2-skewed immune responses, mast cell stabilization, and antioxidant activity—though these mechanisms are supported largely by in vitro and animal data rather than human clinical evidence. Local or raw honey may additionally contain trace allergen exposure hypothesized to induce tolerance, though this desensitization theory lacks robust clinical validation.
Confidence: low
How do realistic dietary honey consumption levels compare to trial doses on a pollen-protein-equivalent basis, and what does this imply mechanistically for symptom relief?
Realistic dietary honey consumption (1–2 tablespoons/day, ~15–30 g) delivers an estimated 60–600 µg of total pollen protein daily, with the allergen-specific fraction (e.g., Bet v 1, Phl p 5, Amb a 1) likely in the sub-microgram to low-microgram range due to mixed floral sources dominated by insect-pollinated plants. This falls substantially below the 10–20 µg/day of standardized major allergen delivered by SLIT/SCIT protocols, and the single well-designed RCT (Rajan et al., 2002) found no symptomatic benefit from 1 tbsp/day over 30 weeks, consistent with this dosing gap. Pollen-enriched or unfiltered local honeys at high intake could theoretically approach low-end therapeutic doses, but remain unstandardized and lack mechanistic validation.
How it works
Allergen immunotherapy achieves desensitization through sustained, dose-controlled allergen exposure that drives regulatory T-cell expansion, IL-10/TGF-β production, IgG4 blocking-antibody induction, and mast-cell/basophil hyporesponsiveness; honey at dietary doses delivers insufficient, variable, and largely digestion-degraded allergen-specific protein to reliably engage these pathways, making any observed benefit more attributable to non-specific anti-inflammatory constituents (flavonoids, phenolics) or placebo rather than genuine allergen-specific desensitization.
Confidence: moderate
Where the evidence runs out
Evidence is predominantly from in vitro cell line models and animal studies, with the effective concentration of 100 µM being pharmacologically challenging to achieve systemically in humans, and no published RCTs have specifically evaluated quercetin's inhibition of mast cell degranulation in allergic rhinitis patients. The treatment duration-dependent effects noted in one study (with prolonged exposure paradoxically increasing degranulation markers) highlight unresolved questions about optimal dosing regimens and bioavailability. There is a notable absence of large, high-quality RCTs specifically targeting allergic rhinitis symptoms in adults or children using standardized omega-3 dosing, making it difficult to draw firm clinical recommendations for this condition. Optimal dosage, EPA/DHA ratios, supplementation timing, and long-term efficacy for allergic rhinitis as a distinct outcome (versus broader atopic or IgE-mediated disease) remain poorly defined. No large-scale RCTs or meta-analyses have rigorously measured blood or tissue histamine levels before and after standardized vitamin C supplementation in allergic rhinitis populations, and proposed mechanisms (DAO cofactor activity, mast cell stabilization) lack robust in vivo human validation. The most recent RCT (2025) found null effects on skin histamine responses, underscoring the need for trials with validated histamine biomarkers, consistent dosing protocols, and adequate sample sizes. Causal directionality remains unestablished—it is unclear whether vitamin D deficiency drives allergic sensitization or whether allergic disease and associated lifestyle changes (e.g., reduced outdoor activity) lead to lower vitamin D levels. Large, well-controlled RCTs specifically targeting allergic rhinitis with standardized vitamin D dosing, baseline stratification, and long-term follow-up are needed to determine whether repletion produces clinically meaningful symptom reduction. There is a near-complete absence of large RCTs or meta-analyses examining high-fibre dietary interventions specifically on allergic rhinitis outcomes in humans, and existing observational data do not adequately distinguish between fibre types, doses, or timing of exposure. Critical uncertainties remain around fibre-type specificity (protective vs. pro-allergic effects), the role of helminth status and baseline microbiome composition, and whether findings from murine models translate meaningfully to human allergic rhinitis. No human RCTs have tested PHGG or inulin specifically in allergic rhinitis or IgE-mediated allergy populations, and no studies have measured IgE suppression or allergen-specific tolerance outcomes for either supplement. Translation of promising mouse model findings and general immune modulation data from healthy cohorts to hayfever or allergic disease contexts remains unvalidated. Large, well-powered RCTs in adults are lacking, and no high-quality trials specifically target allergic rhinitis as distinct from infectious or chronic sinusitis. Standardized dosing protocols, head-to-head comparisons with established first-line therapies (e.g., intranasal corticosteroids, antihistamines), and long-term safety data remain absent from the literature. Evidence for H1 receptor blocking is currently limited to in vitro assays, and it remains unclear whether the IC50 concentrations identified are physiologically achievable following oral administration in humans. Clinical trials are scarce and underpowered, and there are no head-to-head comparisons with standard antihistamines, leaving the clinical relevance of the observed receptor binding largely unestablished. Critical gaps remain in strain and dose standardization, as no head-to-head trials exist to determine optimal probiotic regimens, and most individual RCTs are small (n<100) with high dropout rates that undermine intention-to-treat analyses. Long-term efficacy data, direct gut-nasal microbiome sequencing to confirm mechanistic pathways, and larger seasonal RCTs using standardized outcome measures such as the Total Nasal Symptom Score (TNSS) are needed before definitive clinical recommendations can be made. No human RCTs have isolated the clinical effects of berry anthocyanins, EGCG, or epicatechins on allergic rhinitis symptoms independently of quercetin, leaving the translational significance of robust preclinical data entirely unestablished. Future trials require polyphenol-fractionated dietary interventions with validated AR symptom scoring and biomarker measurement (nasal IgE, IL-6, IL-8, MDA) to determine whether preclinical effect sizes translate to meaningful clinical benefit in hayfever sufferers. No RCTs have evaluated standard commercial green tea (without elevated EGCG3″Me) for allergic rhinitis symptom reduction, making it premature to generalize findings to typical green tea consumption. Critical human-level mechanistic data—including direct quantification of IgE modulation, histamine levels, and Th1/Th2 cytokine profiles in allergic rhinitis patients—are absent, and optimal dosing, long-term safety, and dose-response relationships for EGCG in this indication remain undefined. No large, well-powered RCTs have evaluated oral magnesium supplementation for allergic rhinitis with standardised outcome measures (e.g., TNSS, IgE, histamine biomarkers), and it remains unclear whether physiologically achievable oral doses translate to sufficient mucosal magnesium concentrations to meaningfully stabilise nasal mast cells in vivo. The only available clinical trial is three decades old, underpowered, and lacks quantitative biomarker data, leaving the optimal route of administration, dosage, and patient population entirely unestablished. No post-2011 RCT has used honey with quantified pollen content, standardized modern endpoints (TNSS, RQLQ, medication-use scores), or adequate sample sizes to test the desensitization hypothesis; the sole qualifying RCT (Asha'ari et al.) failed to characterize honey type or pollen content, used an unusually high and impractical dose, lacked validated quality-of-life measures, and was underpowered to detect between-group differences. No large, methodologically rigorous RCTs with standardized honey type, dose, and outcome measures exist, making formal meta-analysis impossible at this time. Critical unknowns include optimal honey type (local/raw vs. commercial), effective dosing, treatment duration, whether any benefit is independent of concurrent antihistamine use, and whether the single positive RCT (Asha'ari et al., 2013) is replicable in other populations. No published trial has quantified the allergen-specific protein content (e.g., µg of Bet v 1 or Phl p 5) in the honey used, making a rigorous pollen-protein-equivalent comparison impossible; mechanistic endpoints such as allergen-specific IgG4, basophil activation, or FOXP3+ Treg counts have not been measured in any controlled honey trial for allergic rhinitis. Pollen-enriched honey preparations remain largely unstudied in well-powered, blinded RCTs with standardized pollen content.
References
- 1.Zhao C, Ding Y, Huang Y et al. · 2024 · Quercetin Attenuates MRGPRX2-Mediated Mast Cell Degranulation via the MyD88/IKK/NF-κB and PI3K/AKT/Rac1/Cdc42 Pathway
- 2.Zhao C, Wang N, Wang C et al. · 2025 · Quercetin Alleviates Chronic Urticaria by Negatively Regulating IgE-Mediated Mast Cell Activation Through CD300f
- 3.Alam S, Wagner A, Willows SD et al. · 2022 · Quercetin and Resveratrol Differentially Decrease Expression of the High-Affinity IgE Receptor (FcεRI) by Human and Mouse Mast Cells
- 4.Luo C, Peng S, Li M et al. · 2022 · The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis
- 5.Farahmandi K, Mohr A, McFarland L et al. · 2022 · Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- 6.Yan S, Ai S, Huang L et al. · 2022 · Systematic review and meta-analysis of probiotics in the treatment of allergic rhinitis
- 7.Zhang Y, Lin J, Zhou R et al. · 2019 · Effect of omega-3 fatty acids supplementation during childhood in preventing allergic disease: a systematic review and Meta-Analysis
- 8.Vahdaninia M, Mackenzie H, Dean T et al. · 2019 · ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: A systematic review and meta-analysis
- 9.Li Q, Zhou Q, Zhang G et al. · 2022 · Vitamin D Supplementation and Allergic Diseases during Childhood: A Systematic Review and Meta-Analysis
- 10.Roschek B, Fink RC, McMichael M et al. · 2009 · Nettle extract (Urtica dioica) affects key receptors and enzymes associated with allergic rhinitis
- 11.Leelakanok N, Petchsomrit A, Janurai T et al. · 2023 · Efficacy and safety of bromelain: A systematic review and meta-analysis
- 12.Passali D, Passali G, Bellussi L et al. · 2018 · Bromelain's penetration into the blood and sinonasal mucosa in patients with chronic rhinosinusitis
- 13.Kazama I, Sonobe H, Shida J et al. · 2025 · Magnesium and Zinc Dose-Dependently Stabilize Rat Peritoneal Mast Cells and Enhance the Effects of Adrenaline
- 14.Fu M, Fu S, Ni S et al. · 2017 · Anti-inflammatory effect of epigallocatechin gallate in a mouse model of ovalbumin-induced allergic rhinitis
- 15.Venter C, Meyer R, Greenhawt M et al. · 2022 · Role of dietary fiber in promoting immune health — An EAACI position paper
- 16.Asha'ari ZA, Ahmad MZ, Din W et al. · 2013 · Ingestion of honey improves the symptoms of allergic rhinitis: evidence from a randomized placebo-controlled trial in the East Coast of Peninsular Malaysia
- 17.Hagel A, Layritz C, Hagel WH et al. · 2013 · Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases
- 18.Lai YR, Liao YH, Huang L et al. · 2025 · Clinical Effects of Polyphenolic Compounds on Allergic Rhinitis: A Systematic Review and Meta-Analysis
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.
